Share Facebook Twitter Pinterest Email Copy Link Novo’s blockbuster drugs could pull it into buzzier areas of healthcare, chief executive Mike Doustdar said, as the Ozempic maker seeks to lessen its reliance on obesity and diabetes. conglomerates consumers
